Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
12/2000
12/14/2000WO2000074702A1 Compositions for the treatment of the catabolic state of prolonged critical illness
12/14/2000WO2000074701A2 Method and composition for inhibiting cardiovascular cell proliferation
12/14/2000WO2000074695A2 Tanacetum parthenium extract
12/14/2000WO2000074687A1 Antisense modulation of b7 protein expression
12/14/2000WO2000074686A1 Modulators of methylation for control of bacterial virulence
12/14/2000WO2000074683A1 Antitumor effect potentiators
12/14/2000WO2000074682A1 Thrombin inhibitors
12/14/2000WO2000074681A1 Metalloprotease inhibitors
12/14/2000WO2000074677A2 Improved pharmaceutical formulations
12/14/2000WO2000074675A1 Antilipemic combinations comprising hmg-coa reductase inhibitors and carnitines
12/14/2000WO2000074670A1 USE OF VERAPAMIL AND VERAPAMIL DERIVATIVES FOR PRODUCING MEDICAMENTS WITH AN INHIBITING EFFECT ON β-GLUCURONIDASE IN HUMAN TISSUE
12/14/2000WO2000074652A1 Pharmaceutical composition for nasally administering water-soluble active substances
12/14/2000WO2000074651A1 Pharmaceutical composition for intranasal use of active substances that are insoluble and/or hardly soluble in water
12/14/2000WO2000074634A2 Methods and compositions for modulating cell proliferation and cell death
12/14/2000WO2000074629A2 Composition for implementing a cytotoxic, in particular an antitumoral or antiviral, treatment in a mammal
12/14/2000WO2000063208B1 Substituted imidazoles, their preparation and use
12/14/2000WO2000049135A3 Substrate for cell growth
12/14/2000WO2000047716A3 Fibres for culturing eukaryotic cells
12/14/2000WO2000047217A3 Protection of cells in connection with treatment with chemical agents
12/14/2000WO2000046386A3 Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
12/14/2000WO2000046228A3 Pyrrolobenzodiazepine carboxyamide vasopressin agonists
12/14/2000WO2000046225A3 Pyridobenzodiazepine and pyridobenzoxazepine carboxyamide vasopressin agonists
12/14/2000WO2000045770A3 Compressed lecithin preparations
12/14/2000WO2000043032A3 Baff, inhibitors thereof and their use in the modulation of b-cell response
12/14/2000WO2000006187A9 Modulation of apoptosis
12/14/2000DE19926154A1 Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung A process for producing an injectable medicament preparation
12/14/2000DE19925810A1 Anwendung von Verapamil und Verapamilderivaten zur Herstellung von Arzneimitteln mit Glucuronidase hemmender Wirkung Application of verapamil and Verapamilderivaten for producing drugs with glucuronidase inhibiting action
12/14/2000CA2378735A1 Process for preparing 10,11-methanobenzosuberane derivatives
12/14/2000CA2377385A1 Methods and compositions for modulating cell proliferation and cell death
12/14/2000CA2376729A1 Small cyclic mimics of brain-derived neurotrophic factor (bdnf)
12/14/2000CA2376506A1 Neuromedin b and somatostatin receptor agonists
12/14/2000CA2376438A1 Identification of compounds that modify transcriptional responses to hypoxia
12/14/2000CA2376400A1 Compounds and methods to enhance raav transduction
12/14/2000CA2376314A1 Apoptosis inhibition by adenovirus e3/6.7k
12/14/2000CA2376210A1 Therapeutic use of an inhibitor of a hedgehog or a hedgehog-related signalling pathway
12/14/2000CA2376199A1 Use of verapamil and verapamil derivatives for producing medicaments with an inhibiting effect on .beta.-glucuronidase in human tissue
12/14/2000CA2376175A1 Vitamin directed dual targeting therapy
12/14/2000CA2376061A1 Pharmaceutical compositions and methods for use
12/14/2000CA2376018A1 Angiogenic proteins and uses thereof
12/14/2000CA2375882A1 Metalloprotease inhibitors
12/14/2000CA2375876A1 An integrin heterodimer and an alpha subunit thereof
12/14/2000CA2375843A1 Compositions and methods for inhibiting cell death
12/14/2000CA2375734A1 Benzothiazinone and benzoxazinone compounds
12/14/2000CA2375148A1 Compositions for the treatment of the catabolic state of prolonged critical illness
12/14/2000CA2375145A1 Substrate trapping protein tyrosine phosphatases
12/14/2000CA2374654A1 Thrombin inhibitors
12/14/2000CA2374460A1 Inhibitors of metalloproteinases
12/14/2000CA2373336A1 Peroxynitrite decomposition catalysts and methods of use thereof
12/14/2000CA2373279A1 Dna methyltransferase inhibitors
12/14/2000CA2371158A1 Diaminothiazoles and their use for inhibiting protein kinases
12/14/2000CA2339900A1 Composition for implementing a cytotoxic, in particular an antitumoral or antiviral, treatment in a mammal
12/13/2000EP1059302A1 Factor VIIa inhibitors
12/13/2000EP1058728A1 V-like domain binding molecules
12/13/2000EP1058725A1 Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria
12/13/2000EP1058692A1 Pf4 fragments and pharmaceutical compositions containing same
12/13/2000EP1058690A1 Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes
12/13/2000EP1058684A1 Glycine transport inhibitors
12/13/2000EP1058683A1 Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof
12/13/2000EP1058681A1 Novel allylthiopyridazine derivatives and process for preparing the same
12/13/2000EP1058680A1 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives as muscarinic receptor antagonists
12/13/2000EP1058559A1 Combination of a selective nmda nr2b antagonist and a cox-2 inhibitor
12/13/2000EP1058555A1 Costimulatory blockade and mixed chimerism in allotransplantation
12/13/2000EP1058545A1 Cancer management with tamoxifen and gammalinolenic acid
12/13/2000EP1058544A1 Inhibition of tnf activity
12/13/2000EP1058542A1 Method for producing encased spherical granular grains
12/13/2000EP0927196A4 Polymers containing polysaccharides such as alginates or modified alginates
12/13/2000EP0725641B1 NOVEL INHIBITORS OF URIDINE PHOSPHORYLASE (UrdPase) AND DIHYDROURACIL DEHYDROGENASE (DHUDase)
12/13/2000EP0724583B1 Pyridazino quinoline compounds
12/13/2000CN1276832A Composition and method for identifying PKB kinase inhibitors
12/13/2000CN1276790A Carboxamidothiazole derivs., preparation, pharmaceutical composition contg. them
12/13/2000CN1276789A 4-aminothiazole derivs, their preparation and their use as inhibitors of cyclin-dependent kinases
12/13/2000CN1276786A 3-aryl-succinamido-hydroxamic acids, method for producing said acids and medicaments contg. same
12/13/2000CN1276729A Heparin-binding growth factor (HBGF) polypeptides
12/13/2000CN1276726A Method for treating hypercoagulable states or acquired protein C deficiency
12/13/2000CN1276721A Use of 6,7-substd. 2-aminotetralines suitable for preparing pharmaceutical composition for therapeutic treatment of inflammatory and/or autoimmune pathologies
12/13/2000CN1276720A Formulations and method for reducing toxicity of antineoplastic agent
12/13/2000CN1276243A Umbilical salves for dropping drug and its preparing process
12/13/2000CN1276221A Anal fissure ointment and its preparing process
12/13/2000CN1276211A Use of non-peptides NK3-antagonist
12/13/2000CN1059466C Method for identifying individuals suffering from cellular abnormality
12/13/2000CN1059436C Benzoazepine-benzooxaazepine-benzothiaazepin-N-acetate deriv.
12/13/2000CN1059433C Arylalkyl (thio) carboxamides, processes forpreparing them and pharmaceutial composition contg. them
12/13/2000CN1059344C Health medicinal liquor and preparation method thereof
12/13/2000CN1059326C Nutrient tea
12/13/2000CN1059321C Iron-cobalt-selenium-copper-arsenic injection
12/12/2000US6160175 Naphthyl acetamides as sPLA2 inhibitors
12/12/2000US6160106 Nucleotide sequences which code polypeptides which prevent gene expression; for use as diagnostic screening tools in the detection and treatment of cancer; anticarcinogenic agents
12/12/2000US6160099 Anti-human αv β3 and αv β5 antibodies
12/12/2000US6160094 Enzymatic polypeptide; for use as a wound healing agent; for use in dentistry to prevent of adhesion of bacteria in wounds
12/12/2000US6160025 Liquid embolic agents
12/12/2000US6160015 Administering to mammal a farnesyl protein transferase inhibitor
12/12/2000US6160012 Leukotriene B4 derivatives, in particular oximo-LTB4 - antagonists
12/12/2000US6160009 Excitatory amino acid receptor modulators
12/12/2000US6160005 Administering alkylenedioxybenzene derivative
12/12/2000US6159996 Polycyclic thiazolidin-2-ylidene amines, process for their preparation, and their use as pharmaceuticals
12/12/2000US6159995 Substituted diaminocarboxylic acids
12/12/2000US6159981 3-substituted pyrido [3',4':4,5] Thieno [2,3-d] pyrimidine derivatives, and production and use of the same
12/12/2000US6159979 Bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5HT1A, 5HT1B and 5HT1D receptor antagonistic activity
12/12/2000US6159978 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
12/12/2000US6159974 LDL receptor gene expression promoters
1 ... 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 ... 1564